|
|
Sydney 2005: Mechanisms of Drug Resistance Towards Thal and IMiDs in MM cells: role of C/EBPb
By Suzanne Lentzsch
|
|
|
04.14.05 |
|
Dr. Lentzsch provided a discussion on the role of C/EBPß, which belongs to a family of transcription factors. C/EBPß plays an important role in the generation of B lymphocytes. Data suggest that C/EBPß may also play a role in the pathogenesis of MM. Given this information, Dr. Lentzsch analyzed the thalidomide derivative CC-4047 (actimid). Similar to thalidomide, CC-4047 has anti-angiogenic properties, but with less side effects. Treatment with CC-4047 in mice with MM tumors induces complete remission that is sustained over the duration of treatment. Dr. Lentzsch tested CC-4047 in cell lines in order to understand the underlying mechanism of action of resistance and sensitivity. Results showed that protein expression of C/EBPß is downregulated in MM cell lines sensitive to CC-4047. She concluded that CC-4047 inhibits growth and angiogenesis better than thalidomide and that C/EBPß may confer resistance to CC-4047. Future studies will be conducted to better understand resistance.
Back to session summary
|
 related articles
|
|
print